Literature DB >> 19643943

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

S C Mathai1, M Bueso, L K Hummers, D Boyce, N Lechtzin, J Le Pavec, A Campo, H C Champion, T Housten, P R Forfia, A L Zaiman, F M Wigley, R E Girgis, P M Hassoun.   

Abstract

N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of neurohormonal activation that is useful in the diagnosis and prognosis of various forms of pulmonary arterial hypertension (PAH). We sought to characterise and compare NT-proBNP in a cohort of PAH related to systemic sclerosis (PAH-SSc) and idiopathic PAH (IPAH) patients. NT-proBNP levels, collected from PAH-SSc and IPAH patients followed prospectively, were compared and correlated with haemodynamic variables. Cox proportional hazard models were created to assess the predictive value of NT-proBNP. 98 patients (55 PAH-SSc, 43 IPAH) were included. Haemodynamics were similar, except for lower mean pulmonary arterial pressure in PAH-SSc. NT-proBNP levels were significantly higher in PAH-SSc (3,419+/-3,784 versus 1,393+/-1,633 pg x mL(-1); p<0.01) and were more closely related to haemodynamics in PAH-SSc than IPAH. 28 patients died. NT-proBNP predicted survival (hazard ratio (HR) 3.18; p<0.01) in the overall cohort; however, when stratified by group, predicted survival only in PAH-SSc (HR 3.07, p<0.01 versus 2.02, p = 0.29 in IPAH). This is the first description showing NT-proBNP levels are 1) significantly higher in PAH-SSc than IPAH despite less severe haemodynamic perturbations, and 2) stronger predictors of survival in PAH-SSc, suggesting that neurohormonal regulation may differ between PAH-SSc and IPAH. Future studies to define pertinent mechanisms are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19643943     DOI: 10.1183/09031936.00074309

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  45 in total

Review 1.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

3.  Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension.

Authors:  Jens Vogel-Claussen; Jan Skrok; Monda L Shehata; Sukhminder Singh; Christopher T Sibley; Danielle M Boyce; Noah Lechtzin; Reda E Girgis; Steven C Mathai; Thomas A Goldstein; Jie Zheng; João A C Lima; David A Bluemke; Paul M Hassoun
Journal:  Radiology       Date:  2010-10-22       Impact factor: 11.105

Review 4.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

5.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

6.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

7.  Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.

Authors:  Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett
Journal:  Chest       Date:  2020-01-25       Impact factor: 9.410

8.  Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.

Authors:  Steven Hsu; Brian A Houston; Emmanouil Tampakakis; Anita C Bacher; Parker S Rhodes; Stephen C Mathai; Rachel L Damico; Todd M Kolb; Laura K Hummers; Ami A Shah; Zsuzsanna McMahan; Celia P Corona-Villalobos; Stefan L Zimmerman; Fredrick M Wigley; Paul M Hassoun; David A Kass; Ryan J Tedford
Journal:  Circulation       Date:  2016-05-11       Impact factor: 29.690

Review 9.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

10.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.